Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CASP2 | P42575 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GLP1R | P43220 | 3/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16420211 | 0.98 | LPAR1 (0.40) | LPAR1LPAR2ENPP2DNM1CNR1 | |
| SCHEMBL14770379 | 0.98 | LPAR1 (0.40) | LPAR1LPAR2ENPP2DNM1CNR1 | |
| SCHEMBL14760918 | 0.92 | LPAR1 (0.38) | LPAR1LPAR2ENPP2DNM1CNR1 | |
| SCHEMBL14773999 | 0.88 | DNM1 (0.49) | LPAR1LPAR2ENPP2DNM1CASP2 | |
| SCHEMBL14770376 | 0.85 | FAAH (0.47) | LPAR1LPAR2ENPP2DNM1CASP2 | |
| SCHEMBL14747173 | 0.79 | LPAR3 (0.45) | LPAR1LPAR2TSHRLPAR3 | |
| SCHEMBL24950256 | 0.78 | CNR1 (0.57) | LPAR1LPAR2ENPP2DNM1CNR1 | |
| SCHEMBL13566316 | 0.78 | CNR1 (0.57) | LPAR1LPAR2ENPP2DNM1CNR1 | |
| SCHEMBL14438836 | 0.78 | CNR1 (0.57) | LPAR1LPAR2ENPP2DNM1CNR1 | |
| SCHEMBL14438834 | 0.78 | CNR1 (0.57) | LPAR1LPAR2ENPP2DNM1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150030541-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2015-01-29 | — | — | US | disclosed |
| US-20150030541-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150030541-A1 | NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES | PHOSPHO1, PHPT1, HPSE | LPAR1 773/4885LPAR2 1113/4885ENPP2 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.